Lepu Biopharma Co., Ltd. Fundamental Analysis
Lepu Biopharma Co., Ltd. (2157.HK) shows moderate financial fundamentals with a PE ratio of 21.48, profit margin of 27.80%, and ROE of 24.17%. The company generates $0.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 2157.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2157.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2157.HK trades at attractive valuation levels.
Growth Score
Weak2157.HK faces weak or negative growth trends.
Financial Health Score
Moderate2157.HK shows balanced financial health with some risks.
Profitability Score
Moderate2157.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 2157.HK Expensive or Cheap?
P/E Ratio
2157.HK trades at 21.48 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 2157.HK's PEG of 0.06 indicates potential undervaluation.
Price to Book
The market values Lepu Biopharma Co., Ltd. at 4.04 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 35.15 times EBITDA. This signals the market has high growth expectations.
How Well Does 2157.HK Make Money?
Net Profit Margin
For every $100 in sales, Lepu Biopharma Co., Ltd. keeps $27.80 as profit after all expenses.
Operating Margin
Core operations generate 5.35 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $24.17 in profit for every $100 of shareholder equity.
ROA
Lepu Biopharma Co., Ltd. generates $8.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Lepu Biopharma Co., Ltd. generates limited operating cash flow of $-35.33M, signaling weaker underlying cash strength.
Free Cash Flow
Lepu Biopharma Co., Ltd. generates weak or negative free cash flow of $-83.47M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.05 in free cash annually.
FCF Yield
2157.HK converts -1.49% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
21.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.04
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.04
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.76
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.98
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.24
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 2157.HK Stacks Against Its Sector Peers
| Metric | 2157.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 21.48 | 29.63 | Better (Cheaper) |
| ROE | 24.17% | 223.00% | Weak |
| Net Margin | 27.80% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.76 | 0.82 | Neutral |
| Current Ratio | 0.98 | 4.30 | Weak Liquidity |
| ROA | 8.31% | -379.00% (disorted) | Weak |
2157.HK outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Lepu Biopharma Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation